Αποτελέσματα Αναζήτησης
The Clinician’s Guide offers concise recommendations regarding prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men aged 50 years and older. It includes indications for bone densitometry as well as fracture risk thresholds for pharmacologic intervention.
A patient with osteoporosis requires comprehensive care, multi- and interdisciplinary intervention, and an individual rehabilitation plan consisting of programmes oriented towards specific areas of intervention.
Purpose of this Guideline. To provide: comprehensive and practical direction for the management of osteoporosis in the primary care setting. evidence-based recommendations based on NICE Clinical Knowledge Summaries (CKS) Osteoporosis – prevention of fragility fractures (March 2016), NICE TA160 Alendronate,
severe osteoporosis (ie, low T-score < −2.5 and fractures) or multiple vertebral fractures, we recommend romosozumab treatment for up to 1 year for the reduction of vertebral, hip, and nonvertebral fractures. Technical remark: The recommended dosage is 210 mg monthly by subcutaneous injection for 12 months.
New or updated topics in this CPG include: clarification of the diagnosis of osteoporosis, stratification of the patient according to high-risk and very-high-risk features, a new dual-action therapy option, and transitions from therapeutic options.
Now, the newly published position paper ‘Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures’ summarizes the guidance in an international setting, with a focus on the categorisation of risk as a strategy to target therapeutic interventions.
ABSTRACT: Depot medroxyprogesterone acetate (DMPA) is a highly effective injectable contraceptive that affords privacy and has a convenient dose schedule of four times per year, making it appealing to many users, especially adolescents.
